Tasigna (nilotinib) in chronic myeloid leukemia treatment-free remission after nearly 2 years: an interview with Adam Mead. (2017)
Attributed to:
Unravelling biological heterogeneity in neoplastic myeloproliferative stem cells
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.2217/fon-2017-0460
PubMed Identifier: 29124948
Publication URI: http://europepmc.org/abstract/MED/29124948
Type: Journal Article/Review
Volume: 13
Parent Publication: Future oncology (London, England)
Issue: 27
ISSN: 1479-6694